Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
ConditionLRG Levels
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorShowa Inan General Hospital
About this trial
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients whom possible UC or Crohn disease was suspected
Disqualifiers
other autoimmune diseases
acute or chronic renal failure
chronic heart diseases
liver cirrhosis
Trial population
In total, a consecutive cohort of 300 patients with possible UC or CD will be enrolled in this study at our hospital.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
serum leucine-rich alpha-2 glycoprotein (LRG) levels
Diagnostic testPatients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Serum LRG measurement
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients.
Time frame
one yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov